Catalyst Pharmaceutical Partners (CPRX) 2.34 $CPRX
Catalyst Pharmaceutical Partners Announces Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the second quarter and six months ended June 30, 2014.
Catalyst Pharmaceutical Partners Provides Updates on Progress of Phase 3 Firdapse Study in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
GlobeNewswire - Mon Aug 11, 7:05AM CDT
Last Patient Completes 2-Week, Blinded Primary Treatment Period - Top-Line Data on Track to Report in 3Q14
Biotech Stock Mailbag: Arrowhead, Catalyst Pharma
at The Street - Fri Aug 01, 7:06AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Global Drug Addiction Clinical Trials Review, H1, 2014 Featuring 20 Top Companies/Institutions
M2 - Tue Jul 01, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3767t/drug_addiction) has announced the addition of the "Drug Addiction Global Clinical Trials Review, H1, 2014" report to their offering. Drug Addiction Global Clinical Trials Review, H1, 2014" provides data on the Drug Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Drug Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Drug Addiction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - RTI International - Johnson & Johnson - Alkermes Inc. (Inactive) - SK Holdings Co., Ltd. - Reckitt Benckiser Group Plc - GlaxoSmithKline plc - Embera NeuroTherapeutics, Inc. - Catalyst Pharmaceutical Partners, Inc. - Gilead Sciences, Inc. - D&A Pharma SAS Clinical Trial Overview of Top Institutes / Government - National Institute on Drug Abuse - Yale University - University of Pennsylvania - New York State Psychiatric Institute - University of California, Los Angeles - Johns Hopkins University - Medical University of South Carolina - Baylor College of Medicine - University of Arkansas - University of Kentucky For more information visit http://www.researchandmarkets.com/research/k3..._addiction
Catalyst Pharmaceutical Partners to Present at the JMP Securities 2014 Healthcare Conference
GlobeNewswire - Thu Jun 19, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the JMP Securities 2014 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Catalyst's Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 24 at 12:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Catalyst Pharmaceutical Partners Set to Join Russell Microcap(R) Index
GlobeNewswire - Wed Jun 18, 12:03PM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced today that the Company is set to join the Russell Microcap(R) Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.
Catalyst Pharmaceutical Partners concludes patient enrollment in pivotal Phase 3 trial of Firdapse in Lambert-Eaton Myasthenic Syndrome patients
M2 - Wed Apr 02, 4:46AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Tuesday the completion of patient enrollment under its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a neuromuscular and neurological disease.
Catalyst Announces Completion of Enrollment in Pivotal Phase 3 Trial of Firdapse(TM) in Patients With Lambert-Eaton Myasthenic Syndrome
GlobeNewswire - Tue Apr 01, 8:25AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines to treat orphan neuromuscular and neurological diseases, announced today that it has reached the patient enrollment target for its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse(TM) for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).
Catalyst Pharmaceutical Partners Expands Executive Leadership Team to Support the Commercialization of Firdapse(TM)
GlobeNewswire - Fri Mar 28, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, FDA-approved medicines targeting orphan neuromuscular and neurological diseases, today announced the appointment of Barrett S. McGrath as Chief Commercial Officer, a newly created position. McGrath will lead the formation of Catalyst's North America commercial strategy and organization. McGrath will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst.
Good News for Catalyst Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:30PM CDT
The independent DMC has recommended the continuation of Catalyst Pharma's phase III study on Firdapse.
Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee to Continue Pivotal Phase 3 Clinical Trial for Firdapse(TM)
GlobeNewswire - Tue Mar 25, 7:17AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced today that, at a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing the Company's ongoing pivotal Phase 3 clinical trial evaluating Firdapse(TM) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the trial be continued as planned based on the committee's review of safety and clinical data from the trial.
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
Catalyst Pharmaceutical Partners (CPRX) in Focus: Stock Moves 6.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:21AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Narrower-than-Expected Loss at Catalyst Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:20AM CDT
Catalyst Pharma incurred a loss of 5 cents in the fourth quarter.
Catalyst Pharmaceutical Partners Announces Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
GlobeNewswire - Wed Mar 19, 7:15AM CDT
Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases today reported financial results for the fourth quarter and year-ended December 31, 2013.
2 Health Care Stocks Under $10 to Trade for Breakouts
at The Street - Mon Mar 17, 6:51AM CDT
Keep these health care stocks on your radar.
Catalyst Pharmaceutical Partners to Present at the 26th Annual ROTH Conference
GlobeNewswire - Thu Mar 06, 8:23AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the 26 Annual ROTH Conference, in California. Steven Miller, Ph.D., Catalyst's Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Monday, March 10 at 10:30 am PT / 1:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
Catalyst Pharmaceutical Partners Observes Rare Disease Day Today
GlobeNewswire - Fri Feb 28, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, joins with the National Organization for Rare Disorders (NORD) in the observance of Rare Disease Day.
Catalyst Pharmaceutical Partners Announces Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the second quarter and six months ended June 30, 2014.
Catalyst Pharmaceutical Partners Provides Updates on Progress of Phase 3 Firdapse Study in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
GlobeNewswire - Mon Aug 11, 7:05AM CDT
Last Patient Completes 2-Week, Blinded Primary Treatment Period - Top-Line Data on Track to Report in 3Q14
Biotech Stock Mailbag: Arrowhead, Catalyst Pharma
at The Street - Fri Aug 01, 7:06AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Global Drug Addiction Clinical Trials Review, H1, 2014 Featuring 20 Top Companies/Institutions
M2 - Tue Jul 01, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3767t/drug_addiction) has announced the addition of the "Drug Addiction Global Clinical Trials Review, H1, 2014" report to their offering. Drug Addiction Global Clinical Trials Review, H1, 2014" provides data on the Drug Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Drug Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Drug Addiction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - RTI International - Johnson & Johnson - Alkermes Inc. (Inactive) - SK Holdings Co., Ltd. - Reckitt Benckiser Group Plc - GlaxoSmithKline plc - Embera NeuroTherapeutics, Inc. - Catalyst Pharmaceutical Partners, Inc. - Gilead Sciences, Inc. - D&A Pharma SAS Clinical Trial Overview of Top Institutes / Government - National Institute on Drug Abuse - Yale University - University of Pennsylvania - New York State Psychiatric Institute - University of California, Los Angeles - Johns Hopkins University - Medical University of South Carolina - Baylor College of Medicine - University of Arkansas - University of Kentucky For more information visit http://www.researchandmarkets.com/research/k3..._addiction
Catalyst Pharmaceutical Partners to Present at the JMP Securities 2014 Healthcare Conference
GlobeNewswire - Thu Jun 19, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the JMP Securities 2014 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Catalyst's Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 24 at 12:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Catalyst Pharmaceutical Partners Set to Join Russell Microcap(R) Index
GlobeNewswire - Wed Jun 18, 12:03PM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced today that the Company is set to join the Russell Microcap(R) Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.
Catalyst Pharmaceutical Partners concludes patient enrollment in pivotal Phase 3 trial of Firdapse in Lambert-Eaton Myasthenic Syndrome patients
M2 - Wed Apr 02, 4:46AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Tuesday the completion of patient enrollment under its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a neuromuscular and neurological disease.
Catalyst Announces Completion of Enrollment in Pivotal Phase 3 Trial of Firdapse(TM) in Patients With Lambert-Eaton Myasthenic Syndrome
GlobeNewswire - Tue Apr 01, 8:25AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines to treat orphan neuromuscular and neurological diseases, announced today that it has reached the patient enrollment target for its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse(TM) for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).
Catalyst Pharmaceutical Partners Expands Executive Leadership Team to Support the Commercialization of Firdapse(TM)
GlobeNewswire - Fri Mar 28, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, FDA-approved medicines targeting orphan neuromuscular and neurological diseases, today announced the appointment of Barrett S. McGrath as Chief Commercial Officer, a newly created position. McGrath will lead the formation of Catalyst's North America commercial strategy and organization. McGrath will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst.
Good News for Catalyst Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:30PM CDT
The independent DMC has recommended the continuation of Catalyst Pharma's phase III study on Firdapse.
Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee to Continue Pivotal Phase 3 Clinical Trial for Firdapse(TM)
GlobeNewswire - Tue Mar 25, 7:17AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced today that, at a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing the Company's ongoing pivotal Phase 3 clinical trial evaluating Firdapse(TM) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the trial be continued as planned based on the committee's review of safety and clinical data from the trial.
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
Catalyst Pharmaceutical Partners (CPRX) in Focus: Stock Moves 6.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:21AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Narrower-than-Expected Loss at Catalyst Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:20AM CDT
Catalyst Pharma incurred a loss of 5 cents in the fourth quarter.
Catalyst Pharmaceutical Partners Announces Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
GlobeNewswire - Wed Mar 19, 7:15AM CDT
Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases today reported financial results for the fourth quarter and year-ended December 31, 2013.
2 Health Care Stocks Under $10 to Trade for Breakouts
at The Street - Mon Mar 17, 6:51AM CDT
Keep these health care stocks on your radar.
Catalyst Pharmaceutical Partners to Present at the 26th Annual ROTH Conference
GlobeNewswire - Thu Mar 06, 8:23AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the 26 Annual ROTH Conference, in California. Steven Miller, Ph.D., Catalyst's Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Monday, March 10 at 10:30 am PT / 1:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
Catalyst Pharmaceutical Partners Observes Rare Disease Day Today
GlobeNewswire - Fri Feb 28, 7:03AM CST
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, joins with the National Organization for Rare Disorders (NORD) in the observance of Rare Disease Day.
